Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Spyre Therapeutics, Inc.

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

	Dec '21	Dec '22	Dec '23
account payables	3.32M -	677K 79.60%	896K 32.35%
accumulated other comprehensive income loss	-20K -	-48K 140%	302K 729.17%
cash and cash equivalents	15.14M -	34.86M 130.24%	188.89M 441.82%
cash and short term investments	93.13M -	55.71M 40.18%	339.28M 508.99%
common stock	5K -	6K 20%	10K 66.67%
deferred revenue	2.36M -	517K 78.08%
deferred revenue non current	1.22M -	2.18M 79.05%
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt	4.62M -	4.00M 13.41%	84.56M 2,011.76%
long term investments	1.84M -	1.55M 15.51%	322K 79.27%
net debt	-10.08M -	-30.23M 199.88%	-104.34M 245.10%
net receivables	815K -	375K 53.99%
other assets
other current assets	4.95M -	6.17M 24.74%	2.25M 63.53%
other current liabilities	14.03M -	12.84M 8.50%	31.08M 142.13%
other liabilities
other non current assets	842K -	683K 18.88%	9K 98.68%
other non current liabilities			41.31M -
othertotal stockholders equity	425.76M -	475.97M 11.79%	763.19M 60.34%
preferred stock			184.93M -
property plant equipment net	8.36M -	6.65M 20.41%
retained earnings	-341.81M -	-425.62M 24.52%	-764.41M 79.60%
short term debt	436K -	625K 43.35%
short term investments	77.99M -	20.85M 73.27%	150.38M 621.34%
tax assets
tax payables
total assets	109.93M -	71.14M 35.28%	341.86M 380.52%
total current assets	98.89M -	62.26M 37.04%	341.53M 448.57%
total current liabilities	20.14M -	14.66M 27.24%	31.98M 118.19%
total debt	5.06M -	4.63M 8.52%	84.56M 1,726.64%
total investments	77.99M -	20.85M 73.27%	150.38M 621.34%
total liabilities	25.98M -	20.84M 19.80%	157.84M 657.44%
total liabilities and stockholders equity	109.93M -	71.14M 35.28%	341.86M 380.52%
total non current assets	11.04M -	8.89M 19.47%	331K 96.28%
total non current liabilities	5.84M -	6.18M 5.86%	125.86M 1,935.66%
total stockholders equity	83.94M -	50.30M 40.07%	184.02M 265.80%

SYRE

COM:SPYRE

Spyre Group

Last Close

27.50

21/11 21:00

Market Cap

1.42B

Beta: -

Volume Today

815.05K

Avg: -

Preview